Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
Philipp von Hundelshausen, Wolfgang Siess
Cancers (2021) Vol. 13, Iss. 5, pp. 1103-1103
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 33-44
Open Access | Times Cited: 110
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
David J. Kuter, Merlin Efraim, Jiřı́ Mayer, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 15, pp. 1421-1431
Open Access | Times Cited: 87
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Aqu Alu, Hong Lei, Xuejiao Han, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 86
Current concepts and novel targets for antiplatelet therapy
Meinrad Gawaz, Tobias Geisler, Oliver Borst
Nature Reviews Cardiology (2023) Vol. 20, Iss. 9, pp. 583-599
Closed Access | Times Cited: 54
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors
Philipp von Hundelshausen, Reinhard Lorenz, Wolfgang Siess, et al.
Thrombosis and Haemostasis (2021) Vol. 121, Iss. 11, pp. 1395-1399
Open Access | Times Cited: 77
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski
Cancers (2022) Vol. 14, Iss. 3, pp. 771-771
Open Access | Times Cited: 47
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak, Tadeusz Robak
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2807-2807
Open Access | Times Cited: 47
A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia
Bingjie Ding, Mengjuan Li, Liu Liu, et al.
Cancer Reports (2025) Vol. 8, Iss. 2
Open Access | Times Cited: 1
The Role of CLEC-2 and Its Ligands in Thromboinflammation
Danyang Meng, Man Luo, Beibei Liu
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 44
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 42
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors
Sarah Dybowski, Sebastian Torke, Martin S. Weber
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 404-404
Closed Access | Times Cited: 16
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
David J. Kuter, Jiřı́ Mayer, Merlin Efraim, et al.
Blood Advances (2024) Vol. 8, Iss. 7, pp. 1715-1724
Open Access | Times Cited: 6
Targeting platelet-derived CXCL12 impedes arterial thrombosis
Julian Leberzammer, Stijn M. Agten, Xavier Blanchet, et al.
Blood (2022) Vol. 139, Iss. 17, pp. 2691-2705
Open Access | Times Cited: 24
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Nichola Cooper, A.J. Gerard Jansen, Robert Bird, et al.
American Journal of Hematology (2025) Vol. 100, Iss. 3, pp. 439-449
Open Access
Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region
Mohamed A. Yassin, Khalil Al Farsi, Anas Hamad, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
Xavier Montalbán, Daniel J. Wallace, Mark C. Genovese, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 1, pp. 1-9
Open Access | Times Cited: 19
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
David J. Kuter, James B. Bussel, Waleed Ghanima, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 11
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Erica V. Lin, Ragha Suresh, Melanie C. Dispenza
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 1, pp. 33-42
Open Access | Times Cited: 4
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
Y Kumagai, Tomoe Fujita, Mika Maeda, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Rilzabrutinib for the Treatment of Immune Thrombocytopenia
Caterina Labanca, Enrica Antonia Martino, Ernesto Vigna, et al.
European Journal Of Haematology (2025)
Open Access
Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
O. А. Shulga, A.S. Romaniuk, O.G. Kotsiuba
Postępy Psychiatrii i Neurologii (2023) Vol. 32, Iss. 1, pp. 23-30
Open Access | Times Cited: 8
The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review
Maria Benkhadra, N. Fituri, Soha Aboukhalaf, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2079-2079
Open Access | Times Cited: 2
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
Vincenzo Nasillo, Ivana Lagreca, Daniela Vallerini, et al.
Cells (2022) Vol. 11, Iss. 6, pp. 1003-1003
Open Access | Times Cited: 12
Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention
Alan Mendez‐Ruiz, Izidore S. Lossos, Mauricio G. Cohen
Journal of the Society for Cardiovascular Angiography & Interventions (2023) Vol. 2, Iss. 3, pp. 100608-100608
Open Access | Times Cited: 6
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis
Michael Hecker, Niklas Frahm, Uwe K. Zettl
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 3-3
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top